We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PerkinElmer Announces Expansion of First-in-Class Epigenetic Research Tools for Drug Discovery

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PerkinElmer Announces Expansion of First-in-Class Epigenetic Research Tools for Drug Discovery"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

“The development of novel therapies aimed at epigenetic drug targets has intensified over the last several years. PerkinElmer is excited to be in the forefront of this research by introducing a wide range of screening reagents that focus on assay selectivity, sensitivity and speed, factors which researchers indicate are critical requirements,” said Martina Bielefeld-Sévigny, Ph.D., vice president and general manager, Drug Discovery and Research Reagent Solutions, Bio-discovery, PerkinElmer.

She added, “It is clear that epigenetic modification plays a key role in cell differentiation and development, as well as in the pathology of cancer and several other disorders. PerkinElmer is committed to providing rapid advances for both academia and the pharmaceutical industry, offering robust enabling tools to work with these important targets.”

Epigenetics is the study of changes in gene activity that are driven by chemical and enzymatic modifications of the DNA and proteins in chromosomes. Epigenetic marks can occur due to environmental factors such as diet, stress or even prenatal care, but can also be heritable.

PerkinElmer’s screening assays for epigenetics are built upon its proprietary homogeneous assay platforms, LANCE®Ultra detection assays for peptide substrates and AlphaLISA® detection assays for both peptide or full-length proteins. Both platforms are no-wash, non-radioactive , antibody-based technologies, that offer a unique combination of specificity, sensitivity, dynamic range  and throughput. All are validated for mark specificity, providing the sensitivity to work with low substrate and enzyme concentrations, generating robust and highly reproducible assay signals.

PerkinElmer’s epigenetic and post-translational screening tools now cover nine different histone marks as well as p53, with more than 15 validated enzyme assays to help researchers discover novel drug compounds directed against several epigenetic enzymes, such as histone methyltransferases (HMTs), demethylases (HDMs),  acetyltransferases (HATs) and deacetylases (HDACs).